US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Praxis Precision Medicines, Inc.

< Previous 1 2 3 4 Next >
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Provides Vormatrigine Program Update
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
News headline image
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Tickers PRAX
< Previous 1 2 3 4 Next >